Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
Status:
Completed
Trial end date:
2017-07-21
Target enrollment:
Participant gender:
Summary
This is a phase II study evaluating the safety, tolerability and efficacy of BKM120 in
patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell
lymphoma (MCL) or follicular lymphoma (FL).